Eva Hoke

899 citations

22 papers · 662 indexed · h-index 14

Impact in

Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 15
- Acute Myeloid Leukemia Research 9
- Chronic Myeloid Leukemia Treatments 7
- Hematopoietic Stem Cell Transplantation 3
Genetics 11
- Chronic Lymphocytic Leukemia Research 11

Co-authors: Richard A. Larson Bayard L. Powell Clara D. Bloomfield Thomas C. Shea Wendy Stock Jonathan E. Kolitz Steven L. Allen Stephen L. George
Journals: Blood (14 papers)Journal of Clinical Oncology (3 papers)Cancer (1 paper)British Journal of Haematology (1 paper)Leukemia (1 paper)
Partner nations: United States Canada

In The Last Decade

Eva Hoke

22 papers receiving 648 citations

Peers

Countries citing papers authored by Eva Hoke

Since Specialization

Citations

This map shows the geographic impact of Eva Hoke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hoke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hoke more than expected).

Fields of papers citing papers by Eva Hoke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hoke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hoke. The network helps show where Eva Hoke may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eva Hoke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Hoke Line = papers co-authored together Eva Hoke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) Leukemia ·William Blum, Ben L. Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey L. Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Eunice S. Wang, Eva Hoke, Krzysztof Mrózek, Jessica Kohlschmidt, Clara D. Bloomfield, Susan Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson	2016	60
2	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results Blood ·Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba‐Prada, Yvonne A. Efebera, Eva Hoke, F Iannetti, Gracienne Gracienne, Vera J. Suman, Paul G. Richardson	2015	17
3	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 British Journal of Haematology ·David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson	2014	57
4	CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure Blood ·Ravi Vij, Vera Hárs, William Blum, Tsiporah B. Shore, Aaron P. Rapoport, Thomas C. Shea, Eva Hoke, Richard M. Stone, Paula N. Friedman, Kouros Owzar, Steven M. Devine	2014	7
5	Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) Haematologica ·Meir Wetzler, D. Watson, Wendy Stock, Anil Singh, Flora Mulkey, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, C. D. Bloomfield, Claudia Linker, Richard A. Larson	2013	68
6	Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 Cancer ·Jonathan E. Kolitz, Stephen L. George, Don M. Benson, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hárs, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson	2013	20
7	Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) Blood ·Meir Wetzler, Dorothy Watson, Wendy Stock, Kouros Owzar, ML Male, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles Linker, Richard A. Larson	2012	5
8	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blood ·William Blum, Ben L. Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey L. Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Meir Wetzler, Eva Hoke, Clara D. Bloomfield, Susan M. Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson	2012	6
9	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101 Journal of Clinical Oncology ·Thomas S. Lin, Kathleen Donohue, John C. Byrd, Margaret S. Lucas, Eva Hoke, Ahmad Rezaee Mazyak, R. Kanti, James N. Atkins, Brian K. Link, Richard A. Larson	2010	61
10	Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Blood ·William Blum, IvanDudinets, Guido Marcucci, Daniel J. DeAngelo, Geoffrey L. Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Meir Wetzler, Eva Hoke, Barry Kurt Moser, Richard A. Larson	2010	2
11	P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 Blood ·Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hárs, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, (unknown)	2010	90
12	Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 Blood ·David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Bayard L. Powell, Thomas C. Shea, Risty Deswinta, Eva Hoke, Bruce D. Cheson, Richard A. Larson	2010	20
13	Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood ·Wendy Stock, Ben L. Sanford, Gerard Lozanski, Ravi Vij, John C. Byrd, Bayard L. Powell, Meir Wetzler, Dorie Sher, Colin G. Edwards, Michael E. Kelly, Sue Richards, Crystal Sung, Greg Malnassy, Eva Hoke, Clara D. Bloomfield, Richard A. Larson	2009	51
14	Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101. Blood ·Thomas S. Lin, Kathleen Donohue, John C. Byrd, Margaret S. Lucas, Eva Hoke, Ahmad Rezaee Mazyak, James N. Atkins, Brian K. Link, R. Kanti, Richard A. Larson	2009	12
15	Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001. Blood ·Meir Wetzler, Wendy Stock, Kathleen Donohue, Kouros Owzar, Dorie A. Sher, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Clara D. Bloomfield, Charles Linker, Richard A. Larson	2007	4
16	Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)—Preliminary results of CALGB 10001 Journal of Clinical Oncology ·Meir Wetzler, Wendy Stock, Kouros Owzar, A. M. DODONOV, Eva Hoke, Claudia Linker, Clara D. Bloomfield, Richard A. Larson	2006	2
17	Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). Blood ·Wendy Stock, Daohai Yu, Ben L. Sanford, Gerard Lozanski, Spero R. Cataland, Ravi Vij, John C. Byrd, Bayard L. Powell, Meir Wetzler, Maher Albitar, Dorie Sher, Colin G. Edwards, Eva Hoke, Clara D. Bloomfield, Richard A. Larson	2005	13
18	Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107. Blood ·Meir Wetzler, Daohai Yu, Olatoyosi Odenike, Eric J. Feldman, David D. Hurd, Eva Hoke, Vera Hárs, Richard A. Larson	2005	1
19	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. Blood ·Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Hamdi Ali SERDAR, Thomas C. Shea, Wendy Stock, Vera Hárs, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson	2005	14
20	Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621 Journal of Clinical Oncology ·Jonathan E. Kolitz, Stephen L. George, Richard K. Dodge, David D. Hurd, Bayard L. Powell, Steven L. Allen, E Vélez-García, Joseph O. Moore, Thomas C. Shea, Eva Hoke, Michael A. Caligiuri, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson	2004	114

About Eva Hoke

Eva Hoke is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Pathology and Forensic Medicine and Immunology, having authored 22 papers that have together received 662 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (13 papers), Chronic Lymphocytic Leukemia Research (11 papers), Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Drug Transport and Resistance Mechanisms (3 papers), Hematopoietic Stem Cell Transplantation (3 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). The work is most often cited by research in Hematology (390 citations), Genetics (157 citations), Pathology and Forensic Medicine (158 citations), Oncology (231 citations) and Public Health, Environmental and Occupational Health (239 citations). Eva Hoke has collaborated with scholars based in United States and Canada. Frequent co-authors include Richard A. Larson, Bayard L. Powell, Clara D. Bloomfield, Thomas C. Shea, Wendy Stock, Jonathan E. Kolitz, Steven L. Allen, Stephen L. George, Guido Marcucci and Ravi Vij. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, British Journal of Haematology and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact